Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of children's media in White, U.S. children's developing racial biases.

The American psychologist·2026
Same author

Deep Continuous-Time State-Space Models for Marked Event Sequences.

Advances in neural information processing systems·2026
Same author

Perceptibility of AI-revised content in pharmacy residency letters of intent.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

Microbiome composition and co-occurrence dynamics in wild <i>Drosophila suzukii</i> are influenced by host crop, fly sex, and sampling location.

Microbiology spectrum·2025
Same author

Platelets in Thrombosis and Atherosclerosis: A Double-Edged Sword.

The American journal of pathology·2024
Same author

A Novel Subcutaneous Furosemide Formulation for Outpatient Management of Heart Failure.

Cardiology in review·2024

Related Experiment Video

Updated: Jul 2, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Metformin use in decompensated heart failure.

Alex Boyd1, James Nawarskas

  • 1Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.

Cardiology in Review
|August 19, 2008
PubMed
Summary

Metformin use in stable heart failure patients with type 2 diabetes is linked to better outcomes. It should not be stopped in stable patients without risk factors for acute decompensated heart failure or lactic acidosis.

More Related Videos

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

Related Experiment Videos

Last Updated: Jul 2, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

Area of Science:

  • Cardiology
  • Endocrinology
  • Nephrology

Background:

  • Metformin is a common treatment for type 2 diabetes.
  • Stable heart failure patients with type 2 diabetes benefit from metformin, showing reduced mortality and morbidity.
  • Elevated systolic blood pressure in diabetic heart failure patients increases the risk of acute decompensated heart failure and kidney dysfunction.

Observation:

  • Metformin-associated lactic acidosis is a rare but serious complication, particularly when kidney function is compromised.
  • Acute decompensated heart failure can lead to decreased kidney function, raising the risk of metformin-associated lactic acidosis.

Findings:

  • Timely intervention during acute decompensated heart failure can preserve kidney function, potentially preventing the threshold for lactic acidosis risk.
  • Metformin can be safely continued in diabetic patients with stable heart failure, provided they lack risk factors for acute decompensated heart failure or lactic acidosis.

Implications:

  • This suggests a careful risk-benefit assessment for metformin use in diabetic heart failure patients.
  • Clinicians should monitor kidney function and heart failure status to optimize metformin therapy.
  • Withholding metformin in stable patients without contraindications may deprive them of its benefits.